NIMRAD (A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab)

PHASE3CompletedINTERVENTIONAL
Enrollment

338

Participants

Timeline

Start Date

September 11, 2014

Primary Completion Date

January 7, 2021

Study Completion Date

January 7, 2021

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

Nimorazole

RADIATION

Radiotherapy

Trial Locations (21)

GL53 7AN

Cheltenham General Hospital, Cheltenham

CH63 4JY

Clatterbridge Centre for Oncology, Bebington

LS9 7TF

St James' Hospital, Leeds

BT9 7AB

Belfast City Hospital, Belfast

B15 2TH

Queen Elizabeth Hospital, Birmingham

BD9 6RJ

Bradford Teaching Hospitals NHS Foundation Trust, Bradford

BS2 8ED

Bristol Haematology and Oncology centre, Bristol

CB2 0QQ

Addenbrookes Hospital, Cambridge

CF14 2TL

Velindre Cancer Centre, Cardiff

CV2 2DX

University Hospitals Coventry and Warwickshire, Coventry

G12 0YN

The Beatson West of Scotland Cancer Centre, Glasgow

GU2 7XX

The Royal Surrey County Hospital, Guildford

LE1 5WW

Leicester Royal Infirmary, Leicester

NW1 2PG

University College London Hospital, London

SW3 6JJ

The Royal Marsden, London

M20 4BX

The Christie NHS Foundation Trust, Manchester

TS4 3BW

The James Cook University Hospital, Middlesbrough

NG5 1PB

Nottingham University Hospitals, Nottingham

S10 2SJ

Weston Park Hospital, Sheffield

SA2 8QA

Singleton Hospital, Swansea

Y031 8HE

York Hospital, York

All Listed Sponsors
lead

The Christie NHS Foundation Trust

OTHER

NCT01950689 - NIMRAD (A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab) | Biotech Hunter | Biotech Hunter